Stockscreener 앱 받기
2.18
0.46%
0.01
시간 외 거래:
2.18
전일 마감가:
$2.17
열려 있는:
$2.21
하루 거래량:
290.14K
Relative Volume:
0.75
시가총액:
$277.03M
수익:
-
순이익/손실:
$-57.09M
주가수익비율:
-4.8262
EPS:
-0.4517
순현금흐름:
$-51.43M
1주 성능:
-3.54%
1개월 성능:
-13.15%
6개월 성능:
+17.20%
1년 성능:
+211.16%
1일 변동 폭
$2.15
$2.28
1주일 범위
$2.15
$2.39
52주 변동 폭
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
명칭
Nautilus Biotechnology Inc
전화
206-333-2001
주소
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.18 | 285.93M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-06-27 | 개시 | Guggenheim | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2022-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 개시 | Cowen | Outperform |
| 2021-08-04 | 개시 | Goldman | Neutral |
| 2021-07-13 | 개시 | Jefferies | Buy |
모두보기
Nautilus Biotechnology Inc 주식(NAUT)의 최신 뉴스
Nautilus Biotechnology (NAUT) Shows Modest Gains Amid Tight Trading RangeNaked POC - newsline.com
Nautilus Biotechnology (NAUT) Edges Higher Amid Biotech Sector Gains; Resistance Test in FocusForce Index - newsline.com
Nautilus Biotechnology (NAUT) Plunges 10.8% as Bearish Momentum BuildsLow Risk Entry Stocks - newsline.com
NAUT Stock Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Tau proteoform quantification research unveiled by Nautilus Biotechnology at ASMS2026 - Traders Union
Andreessen Horowitz (NAUT) funds sell 5M shares, retain near-10% stake - Stock Titan
Andreessen Horowitz funds trim Nautilus (NAUT) stake with 5M-share open-market sale - Stock Titan
Nautilus Biotechnology promotes single molecule proteomics at ASMS with Voyager platform experts - Traders Union
NAUT News | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Surges 5.4% as Biotech Sector Momentum BuildsIntraday Profile - The Legal Advocate
Nautilus Biotechnology (NAUT) Surges Over 5% as Small-Cap Biotech Shows Renewed StrengthMoney Flow - newsline.com
NAUT Q1 2026 Earnings: Narrowed Losses Beat Estimates Amid Platform ProgressEPS Miss Report - The Legal Advocate
Nautilus Biotechnology (NAUT) Pulls Back: Key Levels to Watch After 3.9% DeclineEnding Diagonal - The Legal Advocate
Nautilus Biotechnology (NAUT) Holds Steady at $2.54 as Stock Consolidates Near Key LevelsLow Volatility Picks - Newser
NAUT Stock Price, Quote & Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Q1 2026 Earnings Surprise: EPS $-0.12, Up SignificantStock Analysis Community - Newser
Nautilus Biotechnology Decline Means Insider Profits Down To US$432k - Moomoo
Nautilus Biotechnology introduces Voyager Platform for precise tau proteoform analysis - Traders Union
TradingKey - TradingKey
Nautilus Biotechnology unveils Voyager Platform for quantifying 768 tau proteoforms at Tau Global 2026 - Traders Union
NAUT (Nautilus Biotechnology) quarterly results under review as market awaits full earnings disclosure and segment analysis.Social Buzz Stocks - Newser
Why Nautilus Biotechnology (NAUT) ability to execute stands out (Market Focus) 2026-05-06Fibonacci Fan - thelegaladvocate.com
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
3 Promising Penny Stocks With Market Caps Up To $900M - simplywall.st
Nautilus Biotechnology (NAUT) price target increased by 60.00% to 4.08 - MSN
Nautilus expects cash runway through 2027 while targeting oncology early access in H2 2026 - MSN
What revision trend Nautilus Biotechnology (NAUT)? (Spikes) 2026-05-01Revenue Growth Stocks - newsline.com
Guggenheim Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Nautilus Biotechnology (NAUT) outlines 2026 shareholder votes on directors, pay and auditor - Stock Titan
Nautilus Biotechnology (NASDAQ: NAUT) details Q1 2026 loss and cash runway - Stock Titan
Nautilus Biotechnology Plans Voyager Platform Launch for Late 2026 - HarianBasis.co
Nautilus Biotechnology Q1 Earnings Call Highlights - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Nautilus Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Nautilus Biotechnology Reports First Quarter 2026 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast - Investing.com
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast By Investing.com - Investing.com Canada
Nautilus Biotechnology Q1 net loss narrows as expenses fall - TradingView
Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Q1 2026: Nautilus Biotechnology (NASDAQ: NAUT) cuts costs and narrows loss - Stock Titan
Nautilus Biotechnology 10-Q: $0.0M Revenue, $(0.12) EPS for Q1 2026 - TradingView
Sentinel Trust Co. LBA Purchases New Position in Nautilus Biotechnology, Inc. $NAUT - MarketBeat
Nautilus Biotechnology Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Nautilus Biotechnology launches recruitment drive for Iterative Mapping Early Access Program - Traders Union
Here is why Nautilus Biotechnology (NAUT) is one of the best life sciences penny stocks to buy - MSN
Nautilus Biotechnology CEO joins Biocom panel on AI impact in biotech sector - Traders Union
Nautilus Biotechnology (NAUT) Expected to Announce Earnings on Tuesday - MarketBeat
Nautilus Biotechnology (NAUT) Stock: Fair Value Assessment (Institutional Selling) 2026-04-20High Beta Stocks - Xã Vĩnh Công
Nautilus Biotechnology Inc (NAUT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nautilus Biotechnology Inc 주식 (NAUT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Mar 04 '26 |
Buy |
2.61 |
25,000 |
65,238 |
10,366,721 |
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 05 '25 |
Buy |
0.67 |
116,500 |
78,544 |
10,258,221 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
2.60%
0.94%
자본화:
|
볼륨(24시간):